{"id":11230,"date":"2020-07-17T00:00:00","date_gmt":"2020-07-17T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/","title":{"rendered":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE"},"content":{"rendered":"<p>Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9&nbsp; \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD (comme le l\u00e9nalidomide ou la pomalidomide), un inhibiteur du prot\u00e9asome (comme le bort\u00e9zomib ou le carfilzomib) et un anticorps monoclonal anti-CD38 (comme le daratumumab ou l\u2019isatuximab). Pour lire l&rsquo;article au complet, cliquez <strong><a href=\"https:\/\/www.myeloma.org\/blog\/good-news-fda-panel-votes-approve-belantamab-mafodotin\" target=\"_blank\" rel=\"noopener\">ici<\/a>&nbsp;<\/strong>(en anglais).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9&nbsp; \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[50,50,52,52],"tags":[],"class_list":["post-11230","post","type-post","status-publish","format-standard","hentry","category-news-events","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-07-17T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:19+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#blogposting\",\"name\":\"BONNES NOUVELLES : LE GROUPE D\\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\\u00e9lome Canada\",\"headline\":\"BONNES NOUVELLES : LE GROUPE D\\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-07-17T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#webpage\"},\"articleSection\":\"News &amp; Events, News &amp; Events, What's new at Myeloma Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"position\":3,\"name\":\"Nouvelles de My\\u00e9lome Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#listItem\",\"name\":\"BONNES NOUVELLES : LE GROUPE D\\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#listItem\",\"position\":4,\"name\":\"BONNES NOUVELLES : LE GROUPE D\\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/\",\"name\":\"BONNES NOUVELLES : LE GROUPE D\\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\\u00e9lome Canada\",\"description\":\"Mardi 14 juillet, les membres de l\\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food & Drug Administration des \\u00c9tats-Unis ont vot\\u00e9 \\u00e0 l\\u2019unanimit\\u00e9 (12 contre 0) en faveur de l\\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\\u2019un my\\u00e9lome r\\u00e9cidivant ou r\\u00e9fractaire. Les patients doivent avoir re\\u00e7u au moins quatre traitements ant\\u00e9rieurs, dont un IMiD\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/07\\\/17\\\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2020-07-17T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada","description":"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food & Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD","canonical_url":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#blogposting","name":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada","headline":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2020-07-17T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#webpage"},"articleSection":"News &amp; Events, News &amp; Events, What's new at Myeloma Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","position":3,"name":"Nouvelles de My\u00e9lome Canada","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#listItem","name":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#listItem","position":4,"name":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/","name":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada","description":"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food & Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2020-07-17T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada","og:description":"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD","og:url":"https:\/\/myeloma.ca\/fr\/2020\/07\/17\/bonnes-nouvelles-le-groupe-dexperts-de-la-fda-vote-en-faveur-du-belantamab-mafodotine\/","article:published_time":"2020-07-17T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:19+00:00","twitter:card":"summary_large_image","twitter:title":"BONNES NOUVELLES : LE GROUPE D\u2019EXPERTS DE LA FDA VOTE EN FAVEUR DU BELANTAMAB MAFODOTINE | My\u00e9lome Canada","twitter:description":"Mardi 14 juillet, les membres de l\u2019ODAC (Oncologic Drugs Advisory Committee) de la Food &amp; Drug Administration des \u00c9tats-Unis ont vot\u00e9 \u00e0 l\u2019unanimit\u00e9 (12 contre 0) en faveur de l\u2019approbation du belantamab mafodotine (Bela) pour le traitement d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. Les patients doivent avoir re\u00e7u au moins quatre traitements ant\u00e9rieurs, dont un IMiD"},"aioseo_meta_data":{"post_id":"11230","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:02:42","updated":"2026-04-30 07:24:30","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11230"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230\/revisions"}],"predecessor-version":[{"id":31317,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11230\/revisions\/31317"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}